$IPSC

Century Therapeutics (NASDAQ: IPSC) aims to file for FDA approval of its diabetes cell therapy, CNTY-813, in Q4 2026, with initial human data expected in 2027. The company reported $197.2M in cash as of Q2 2026, sufficient to fund operations into Q1 2029. Preclinical results showed promising glucose control and immune evasion, but clinical outcomes are not guaranteed. Century also advances CNTY-308, a CAR-iT cell therapy, with IND-enabling work on track for 2026. Q2 R&D expenses decreased 27% to

Century Therapeutics, Inc. (IPSC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates · Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track f

BioPharma Dive roundup covers AstraZeneca’s eplontersen failure in a major heart disease study, boosting expectations for rival TTR amyloidosis drugs from Alnylam and BridgeBio. Other items include ARPA-H funding, GSK ending a neuroscience alliance with Alector, Vera Therapeutics’ FDA nod for IgA nephropathy, and Vertex’s $10B plan to buy Crinetics.

Century Therapeutics (NASDAQ:IPSC) said abstracts for CNTY-813 were accepted for oral presentations at the 62nd EASD meeting (Sep 28-Oct 2, 2026, Milan) and the Breakthrough T1D Congress (Oct 9-11, 2026, Philadelphia). The iPSC-derived islet therapy uses Allo-Evasion 5.0. Company targets an IND submission in Q4 2026 and expects initial clinical data in H2 2027, citing June preclinical results.

Century Therapeutics (NASDAQ: IPSC) said its abstracts were accepted for oral presentations at EASD 2026 (Sept 28-Oct 2, Milan) and Breakthrough T1D CRC 2026 (Oct 9-11, Philadelphia). Both will feature preclinical data on CNTY-813, an Allo-Evasion 5.0 engineered iPSC-derived islet therapy for type 1 diabetes, with an IND targeted for Q4 2026.

Century Therapeutics, Inc. (IPSC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001850119 0001850119 2026-06-15 2026-06-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report

Century Therapeutics, Inc. (IPSC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false --12-31 0001850119 0001850119 2026-06-11 2026-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of

Century Therapeutics (NASDAQ: IPSC) presented new preclinical results for CNTY-813, an iPSC-derived islet replacement engineered with Allo-Evasion™ 5.0, at ADA 2026. The company said transplanted cells maintained normoglycemia for over eight months in mice, with glucose normalization within 60 minutes in glucose tolerance tests. It also reported >50% beta-cell composition, no tumorigenesis in >140 mice, and immune evasion in humanized models without immunosuppression. Century said Phase 1 manufa

Century Therapeutics (IPSC) has filed a prospectus supplement to register an "at-the-market" (ATM) shelf offering of up to $150 million in common stock through TD Cowen. Approximately $131.6 million remains available under this offering, with sales to be made at market prices and TD Cowen receiving a 3.0% commission. The net proceeds are intended for general corporate purposes, including research, clinical development, manufacturing, working capital, and capital expenditures.

Century Therapeutics (IPSC) reported a significant swing to a basic EPS profit of US$0.51 for the first half of 2025, with revenues of US$109.2 million, contrasting its prior periods of losses. Despite this positive half-year performance, the company still maintains a net loss of US$9.6 million over the trailing twelve months, and analysts forecast a decline in earnings over the next three years. The article discusses how this recent profitability challenges previous narratives of persistent losses but highlights the fragility of earnings and the company's valuation below its biotech peers.